Drug Search Results
More Filters [+]

Veliflapon

Alternative Names: veliflapon, dg-031
Latest Update: 2006-11-29
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: FLAP Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Veliflapon

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Acute Coronary Syndrome|Angina, Unstable|Angina, Stable

Phase 2: Myocardial Infarction|Coronary Artery Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2005-002145-39

P2

Completed

Myocardial Infarction

2005-12-14

2004-004980-30

P2

Completed

Coronary Artery Disease

2005-03-14

The LTCAD Study

P3

Suspended

Acute Coronary Syndrome|Angina, Unstable|Angina, Stable

None

Recent News Events

Date

Type

Title